Prognostic significance of o-glcnac and pkm2 in hormone receptor-positive and her2-nonenriched breast cancer

Wen Ling Kuo, Lin Lu Tseng, Che Chang Chang, Chih Jung Chen, Mei Ling Cheng, Hsin Hung Cheng, Meng Jen Wu, Yu Lun Chen, Ruei Ting Chang, Hsiang Yu Tang, Yong Chen Hsu, Wen Jye Lin, Cheng Yuan Kao, Wen Ping Hsieh, Hsing Jien Kung, Wen Ching Wang

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Predictive metabolic biomarkers for the recurrent luminal breast cancer (BC) with hormone receptor (HR)-positive and human epidermal growth factor receptor type 2 (HER2)-negative are lacking. High levels of O-GlcNAcylation (O-GlcNAc) and pyruvate kinase isoenzyme M2 (PKM2) are associated with malignancy in BC; however, the association with the recurrence risk remains unclear. We first conduct survival analysis by using the METABRIC dataset to assess the correlation of PKM2 expression with BC clinical outcomes. Next, patients with HR+/HER2-luminal BC were recruited for PKM2/O-GlcNAc testing. Logistic regression and receiver operating characteristic curve analysis were performed to evaluate the 10-year DFS predicted outcome. Survival analysis of the METABRIC dataset revealed that high expression of PKM2 was significantly associated with worse overall survival in luminal BC. The high expression of O-GlcNAc or PKM2 was a significant independent marker for poor 10-year DFS using immunohistochemical analysis. The PKM2 or O-GlcNAc status was a significant predictor of DFS, with the combination of PKM2–O-GlcNAc status and T stage greatly enhancing the predictive outcome potential. In summary, O-GlcNAc, PKM2, and T stage serve as good prognostic discriminators in HR+/HER2 luminal BC.

Original languageEnglish
Article number1460
Issue number8
Publication statusPublished - Aug 2021


  • HR/HER2 luminal breast cancer
  • Metabolism
  • O-GlcNAc
  • PKM2
  • Prognosis

ASJC Scopus subject areas

  • Clinical Biochemistry


Dive into the research topics of 'Prognostic significance of o-glcnac and pkm2 in hormone receptor-positive and her2-nonenriched breast cancer'. Together they form a unique fingerprint.

Cite this